Savara Pharmaceuticals announced the publication of two case reports demonstrating that inhaled granulocyte-macrophage colony stimulating factor (GM-CSF) either eradicated or…
Articles by Iqra Mumal MSc
Humanigen’s anti-inflammatory therapy KB001-A is safe but only modestly effective in cystic fibrosis patients with a Pseudomonas aeruginosa bacteria infection, a Phase 2…
The overall rate at which women with cystic fibrosis are becoming pregnant dropped slightly in recent years — coinciding with…
Vertex Pharmaceuticals, a clinical-stage biopharmaceutical company, recently announced that two Phase 3 studies evaluating its tezacaftor/ivacaftor combination therapy have…
Corbus Pharmaceuticals recently announced that the U.S. Patent and Trademark Office has issued a patent for the use of…
Pulmatrix recently announced that it is presenting positive preclinical data on its antifungal therapy Pulmazole at the North American Cystic…
A new tool allows researchers and doctors to visualize a 3D model of a cystic fibrosis (CF) lung that…
The National Institutes of Health (NIH) has awarded Exotect a $224,576 Small Business Technology Transfer grant to develop small molecule therapies to…
The risk of cystic fibrosis patients with chronic Achromobacter infections dying or having to have a lung transplant is twice as…
Magnetic resonance imaging (MRI) scans, already important to both doctors treating patients and researchers conducting trials, might soon distinguish diseased and…